PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Top Cited Papers
Open Access
- 1 June 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 9 (6), 722-737
- https://doi.org/10.1158/2159-8290.cd-18-1218
Abstract
Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we sought to dissect the mechanisms underlying PARP inhibitor–induced changes in the tumor microenvironment of BRCA1-deficient triple-negative breast cancer (TNBC). We demonstrate that the PARP inhibitor olaparib induces CD8+ T-cell infiltration and activation in vivo, and that CD8+ T-cell depletion severely compromises antitumor efficacy. Olaparib-induced T-cell recruitment is mediated through activation of the cGAS/STING pathway in tumor cells with paracrine activation of dendritic cells and is more pronounced in HR-deficient compared with HR-proficient TNBC cells and in vivo models. CRISPR-mediated knockout of STING in cancer cells prevents proinflammatory signaling and is sufficient to abolish olaparib-induced T-cell infiltration in vivo. These findings elucidate an additional mechanism of action of PARP inhibitors and provide a rationale for combining PARP inhibition with immunotherapies for the treatment of TNBC. Significance: This work demonstrates cross-talk between PARP inhibition and the tumor microenvironment related to STING/TBK1/IRF3 pathway activation in cancer cells that governs CD8+ T-cell recruitment and antitumor efficacy. The data provide insight into the mechanism of action of PARP inhibitors in BRCA-associated breast cancer. This article is highlighted in the In This Issue feature, p. 681Keywords
Funding Information
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (P50 CA168504)
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (R01 CA090687)
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (R01 CA226776)
- Susan G. Komen for the CureSusan G. Komen for the Cure (Susan G. Komen) (CCR18547597)
- EC | European Research CouncilEC | European Research Council (ERC) (CoG-681572)
This publication has 44 references indexed in Scilit:
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistanceProceedings of the National Academy of Sciences of the United States of America, 2013
- Cyclic Dinucleotides Trigger ULK1 (ATG1) Phosphorylation of STING to Prevent Sustained Innate Immune SignalingCell, 2013
- Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer RegistryClinical Cancer Research, 2013
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary TumorsCancer Discovery, 2013
- Molecular basis of Tank-binding kinase 1 activation by transautophosphorylationProceedings of the National Academy of Sciences of the United States of America, 2012
- Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancerBreast Cancer Research and Treatment, 2011
- Direct Effects of Type I Interferons on Cells of the Immune SystemClinical Cancer Research, 2011
- Triple-negative breast cancer: disease entity or title of convenience?Nature Reviews Clinical Oncology, 2010
- Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancerProceedings of the National Academy of Sciences of the United States of America, 2007
- Identification of the Minimal Phosphoacceptor Site Required for in Vivo Activation of Interferon Regulatory Factor 3 in Response to Virus and Double-stranded RNAPublished by Elsevier BV ,2003